Effects of Chromatin Function Inhibitors on Yeast Whole Cells and Spheroplasts

Abstract

Saccharomyces cerevisiae has long been used as an alternative experimental model in the study of cancer and anticancer drug action. Although this simple eukaryote has provided useful information, its value as an experimental model is often controversial due to the presence of the cell wall — a cellular structure which is absent in higher eukaryotes. The aim of this study was to investigate the possible involvement of the cell wall in the ineffectiveness of some anticancer drugs in yeast, by enzymatic removal of the cell wall. The effects of exposing whole-cell cultures and spheroplasts to chromatin function inhibitors for 22 hours were investigated. Vinblastine, etoposide and paclitaxel had no cytotoxic effects on whole-cell cultures either with or without the addition of verapamil. The growth profiles of yeast spheroplasts following drug exposure were similar to those observed in whole cells. These data demonstrate that the resistance of the lower eukaryote to these drugs was not overcome by the enzymatic removal of the cell wall.

Keywords

chromatin function inhibitors yeast spheroplasts

Get full access to this article

View all access options for this article.

References

Gause

G.F.

, & Laiko

A.V.

(1978). Yeast mutants with distorted cell membranes as a detection system for antitumor antibiotics. Antibiotics and Chemotherapy 23, 21–25.

White

R.J.

(1982). Microbiological models as screening tools for anticancer agents: potentials and limitations. Annual Review of Microbiology 36, 415–433.

Botstein

, & Fink

G.R.

(1988). Yeast: an experimental organism for modern biology. Science 240, 1439–1443.

Herskowitz

(1988). Life cycle of the budding yeast Saccharomyces cerevisiae. Microbiological Reviews 52, 536–553.

Hartwell

L.H.

(1992). Role of yeast in cancer research. Cancer 69, 2615–2621.

Deutch

C.E.

, & Parry

J.M.

(1974). Spheroplast formation in yeast during the transition from exponential phase to stationary phase. Journal of General Microbiology 80, 259–268.

Nitiss

, & Wang

J.C.

(1988). DNA topoisomerase-targeting antitumour drugs can be studied in yeast. Proceedings of the National Academy of Sciences, USA 85, 7501–7505.

Tiligada

, & Delitheos

(1993). Involvement of potassium ions in the action of various anti-neoplastic drugs on the growth of Saccharomyces cerevisiae. Letters in Applied Microbiology 16, 251–253.

Delitheos

, Tiligada

, Stavrinidis

, Manolis

, & Vovou

(1995). Effect of antineoplastic drugs on Saccharomyces cerevisiae under stress conditions. Anticancer Research 15, 2921.

10.

Tiligada

, Giannakakou

, Karavokyros

, & Delitheos

(1996). Effect of calcium channel blockers on the action of various antitumour agents in the yeast Saccharomyces cerevisiae. Journal of Applied Bacteriology 81, 481–485.

11.

Raymond

, Ruetz

, Thomas

D.Y.

, & Gros

(1994). Functional expression of P-glycoprotein in Saccharomyces cerevisiae confers cellular resistance to the immunosuppressive and antifungal agent FK520. Molecular and Cellular Biology 14, 277–286.

12.

Hutchison

H.T.

, & Hartwell

L.H.

(1967). Macro-molecule synthesis in yeast spheroplasts. Journal of Bacteriology 94, 1697–1705.

13.

Delitheos

, Karavokyros

, & Tiligada

(1995). Response of Saccharomyces cerevisiae strains to antineoplastic agents. Journal of Applied Bacteriology 79, 379–383.

14.

American Type Culture Collection (1987). Catalogue of Fungi Yeast, 325 pp. Rockville, MD, USA: ATCC.

15.

American Type Culture Collection (1995). ATCC Yeast, 108 pp. Rockville, MD, USA: ATCC.

16.

Scott

J.H.

, & Schekman

(1980). Lyticase: endoglucanase and protease activities that act together in yeast cell lysis. Journal of Bacteriology 142, 414–423.

17.

Henschke

P.A.

, Thomas

D.S.

, Rose

A.H.

, & Veazey

(1983). Association of intracellular low-density vesicles with plasma membranes from Saccharomyces cerevisiae NCYC 366. Journal of General Microbiology 129, 2927–2938.

18.

Lee

S.S.

, Robinson

S.M.

, & Wang

H.Y.

(1981). Rapid determination of yeast viability. Biotechnology Bioengineering Symposia 11, 641–649.

19.

Tiligada

, Stavrinidis

, & Delitheos

(1997). Effect of tamoxifen in lower eukaryotic cells. Anticancer Research 17, 4098.

20.

Mariani

, Prosperi

, Colombo

, & Supino

(1989). Doxorubicin resistance circumvention by verapamil in B19 melanoma cells. Anticancer Research 9, 29–32.

21.

Tsuruo

, Iida

, Tsukagoshi

, & Sakurai

(1983). Potentiation of vincristine and adri-amycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors. Cancer Research 43, 2267–2272.

22.

Fojo

A.T.

(1991). Multidrug resistance. Advances in Internal Medicine 36, 195–218.

23.

Pratt

W.B.

, Ruddon

R.W.

, Ensminger

W.D.

, & Maybaum

(1994). The Anticancer Drugs, 2nd edn, 352 pp. New York, USA: Oxford University Press.

24.

Zwelling

L.A.

(1989). Topoisomerase II as a target of antileukemia drugs: a review of controversial areas. Hematology and Pathology 3, 101–112.

25.

Danks

M.K.

, Yalowich

J.C.

, & Beck

W.T.

(1987). Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). Cancer Research 47, 1297–1301.